Gilead’s CAR-T Drug Outperforms Standard of Care in B-Cell Lymphoma Trial
On June 28th, Kite, a company of Gilead, announced that Yescarta, a CAR-T therapy improved event-free survival when compared with second-line standard of care therapy in relapsed or refractory large …
Read More